May 11, 2012 — In the wake of the June 2011 U.S. Supreme Court decision in IMS v. Sorrell, which stated that a Vermont law violated the First Amendment because it restricted the sale of prescription drug data for commercial marketing purposes, the New Hampshire legislature recently amended a similar law on its books by […]
Read moreTag: rx data
rx dataFall 2011 Update: Four Things Industry Should Know
By John Kamp, Coalition for Healthcare Communication Executive Director Sept. 13, 2011 — Debates over health care and related marketing costs are certain to arise as the Congress and White House struggle to reduce the deficit, stimulate the economy and prepare for the upcoming elections. Meanwhile, the IMS Supreme Court decision is causing a […]
Read moreExperts Weigh In on Implications of Sorrell Decision
Aug. 1, 2011 — The recent Supreme Court decision in Sorrell v. IMS Health Inc. is earning robust commentary in the legal community because it extends greater First Amendment protection for marketing and expands that protection to data mining and use. In addition, many legal scholars openly are questioning whether the FDA can continue its […]
Read moreFrom The RPM Report: Data Mining Case Struck Down by Supreme Court; IMS Prepares for Future Battles
July 27, 2011 — A recent article written by Kate Rawson in The RPM Report provides an excellent summary of the Supreme Court”s decision in Sorrell v. IMS Health Inc. and discusses the decision”s implications for the pharmaceutical industry. Coalition for Healthcare Communication Executive Director John Kamp is quoted in this insightful article, which is reprinted below, with permission. […]
Read moreSorrell v. IMS: What Marketing Professionals Need to Know
By John Kamp, Executive Director, Coalition for Healthcare Communication July 18, 2011 — For those who have not read the entire June 23 Sorrell v. IMS Health Inc. Supreme Court decision (No. 10-779), here is a quick summary of what happened and what drug marketing executives need to know. Top line, the Supreme Court majority […]
Read moreNEWS ALERT: U.S. Supreme Court Deems Vermont Marketing Ban To Be in Violation of First Amendment
June 23, 2011 — In a victory for data gathering companies, the pharmaceutical and biotechnology industries, advertising agencies, medical publishers and other media, the U.S. Supreme Court ruled in Sorrell v. IMS Health Inc. today that Vermont’s ban on marketing use of prescription data “turns on nothing more than a difference of opinion” and that […]
Read moreDo Not Track: Coming Soon to a Mobile Device Near You?
May 27, 2011 — As Congress considers six pieces of pending legislation introduced to protect consumers’ privacy online – all but one of which recommends mandatory “Do Not Track” provisions – the Senate Committee on Commerce, Science & Transportation last week held a hearing to discuss whether Do Today saw a good website Not Track […]
Read moreRequired Course for Medical Agencies: 4A’s Webinar on Your Role in Implementing the Behavioral Advertising Self-Regulation Program
May 17, 2011 — Widespread industry participation in online behavioral advertising (OBA) self-regulation is the only way for the program to succeed and for advertisers to stave off federal regulation of behavioral marketing practices, according to Dick O’Brien, head of the 4A’s Washington office and moderator of an OBA educational Webinar for ad agencies. “Do […]
Read moreTwo More “Do Not Track” Bills Enter the Fray
May 13, 2011 – In the span of one week, two new bills calling for “Do Not Track” provisions were introduced in Congress, increasing the pressure on lawmakers to address the various versions of Do Not Track legislation that have been introduced during the past few months. On May 9, Sen. John D. “Jay” Rockefeller […]
Read moreUPDATE: Supreme Court finds Rx data use ban violates the First Amendment
June 23, 2011 — Justices find Vermont violated First Amendment rights of pharma and data publishers Sweeping aside justifications by the state of Vermont and privacy advocates, the United States Supreme Court today found the Vermont ban on marketing use of Rx data a violation of the First Amendment. ” This is a victory for patients as […]
Read more